RAPT Stock Overview
Operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
RAPT Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.84 |
| 52 Week High | US$4.83 |
| 52 Week Low | US$0.71 |
| Beta | -0.040 |
| 1 Month Change | 6.07% |
| 3 Month Change | -30.13% |
| 1 Year Change | -79.04% |
| 3 Year Change | -93.32% |
| 5 Year Change | -95.34% |
| Change since IPO | -93.55% |
Recent News & Updates
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Mar 28
Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904
Feb 16Recent updates
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Mar 28Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904
Feb 16Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?
Nov 10RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15Shareholder Returns
| RAPT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | 1.4% | 2.9% |
| 1Y | -79.0% | -14.7% | 11.9% |
Return vs Industry: RAPT underperformed the US Biotechs industry which returned -14.7% over the past year.
Return vs Market: RAPT underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| RAPT volatility | |
|---|---|
| RAPT Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: RAPT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RAPT's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 67 | Brian Wong | www.rapt.com |
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.
RAPT Therapeutics, Inc. Fundamentals Summary
| RAPT fundamental statistics | |
|---|---|
| Market cap | US$110.92m |
| Earnings (TTM) | -US$116.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs RAPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAPT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$116.51m |
| Earnings | -US$116.51m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RAPT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 21:56 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RAPT Therapeutics, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leiyang Wang | Barclays |
| Gao Yi Chen | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |